These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 38717141)

  • 1. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
    Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
    mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
    Deniskin R; Frame IJ; Sosa Y; Akabas MH
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoproteomics validates selective targeting of
    Giannangelo C; Challis MP; Siddiqui G; Edgar R; Malcolm TR; Webb CT; Drinkwater N; Vinh N; Macraild C; Counihan N; Duffy S; Wittlin S; Devine SM; Avery VM; De Koning-Ward T; Scammells P; McGowan S; Creek DJ
    Elife; 2024 Jul; 13():. PubMed ID: 38976500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and chemical validation of
    Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
    Elife; 2022 Sep; 11():. PubMed ID: 36097817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local emergence in Amazonia of
    Mathieu LC; Cox H; Early AM; Mok S; Lazrek Y; Paquet JC; Ade MP; Lucchi NW; Grant Q; Udhayakumar V; Alexandre JS; Demar M; Ringwald P; Neafsey DE; Fidock DA; Musset L
    Elife; 2020 May; 9():. PubMed ID: 32394893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retargeting azithromycin analogues to have dual-modality antimalarial activity.
    Burns AL; Sleebs BE; Siddiqui G; De Paoli AE; Anderson D; Liffner B; Harvey R; Beeson JG; Creek DJ; Goodman CD; McFadden GI; Wilson DW
    BMC Biol; 2020 Sep; 18(1):133. PubMed ID: 32993629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites.
    Bosson-Vanga H; Primas N; Franetich JF; Lavazec C; Gomez L; Ashraf K; Tefit M; Soulard V; Dereuddre-Bosquet N; Le Grand R; Donnette M; Mustière R; Amanzougaghene N; Tajeri S; Suzanne P; Malzert-Fréon A; Rault S; Vanelle P; Hutter S; Cohen A; Snounou G; Roques P; Azas N; Lagardère P; Lisowski V; Masurier N; Nguyen M; Paloque L; Benoit-Vical F; Verhaeghe P; Mazier D
    Microbiol Spectr; 2021 Oct; 9(2):e0027421. PubMed ID: 34724729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
    Le Bihan A; de Kanter R; Angulo-Barturen I; Binkert C; Boss C; Brun R; Brunner R; Buchmann S; Burrows J; Dechering KJ; Delves M; Ewerling S; Ferrer S; Fischli C; Gamo-Benito FJ; Gnädig NF; Heidmann B; Jiménez-Díaz MB; Leroy D; Martínez MS; Meyer S; Moehrle JJ; Ng CL; Noviyanti R; Ruecker A; Sanz LM; Sauerwein RW; Scheurer C; Schleiferboeck S; Sinden R; Snyder C; Straimer J; Wirjanata G; Marfurt J; Price RN; Weller T; Fischli W; Fidock DA; Clozel M; Wittlin S
    PLoS Med; 2016 Oct; 13(10):e1002138. PubMed ID: 27701420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation.
    Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ
    mBio; 2020 Jan; 11(1):. PubMed ID: 31992618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
    Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Variant PfCRT Isoform Can Contribute to
    Dhingra SK; Redhi D; Combrinck JM; Yeo T; Okombo J; Henrich PP; Cowell AN; Gupta P; Stegman ML; Hoke JM; Cooper RA; Winzeler E; Mok S; Egan TJ; Fidock DA
    mBio; 2017 May; 8(3):. PubMed ID: 28487425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction.
    Lo E; Nguyen J; Oo W; Hemming-Schroeder E; Zhou G; Yang Z; Cui L; Yan G
    BMC Infect Dis; 2016 Apr; 16():154. PubMed ID: 27084511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analyses of the malaria parasite aminoacyl-tRNA synthetases provide new avenues for antimalarial drug discovery.
    Chhibber-Goel J; Yogavel M; Sharma A
    Protein Sci; 2021 Sep; 30(9):1793-1803. PubMed ID: 34184352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium berghei K13 Mutations Mediate
    Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
    mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
    Vinh NB; Drinkwater N; Malcolm TR; Kassiou M; Lucantoni L; Grin PM; Butler GS; Duffy S; Overall CM; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2019 Jan; 62(2):622-640. PubMed ID: 30537832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the substrate specificity of the Plasmodium M1 and M17 aminopeptidases.
    Malcolm TR; Swiderska KW; Hayes BK; Webb CT; Drag M; Drinkwater N; McGowan S
    Biochem J; 2021 Jul; 478(13):2697-2713. PubMed ID: 34133730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
    McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.
    Calic PPS; Vinh NB; Webb CT; Malcolm TR; Ngo A; Lowes K; Drinkwater N; McGowan S; Scammells PJ
    Eur J Med Chem; 2023 Feb; 248():115051. PubMed ID: 36634455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.